{"id":235698,"date":"2026-04-22T10:15:33","date_gmt":"2026-04-22T15:15:33","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/04\/hypertension-with-high-risk-features-in-cryptogenic-stroke-an-exploratory-analysis-of-the-arcadia-randomized-clinical-trial"},"modified":"2026-04-22T10:15:33","modified_gmt":"2026-04-22T15:15:33","slug":"hypertension-with-high-risk-features-in-cryptogenic-stroke-an-exploratory-analysis-of-the-arcadia-randomized-clinical-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/04\/hypertension-with-high-risk-features-in-cryptogenic-stroke-an-exploratory-analysis-of-the-arcadia-randomized-clinical-trial","title":{"rendered":"Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Clinical Trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/hypertension-with-high-risk-features-in-cryptogenic-stroke-an-exploratory-analysis-of-the-arcadia-randomized-clinical-trial.png\"><\/a><\/p>\n<p>In an exploratory analysis of the ARCADIA randomized clinical trial, hypertension with high\u2011risk features was associated with modification of antithrombotic treatment effects after cryptogenic stroke. Among patients without high\u2011risk hypertension features, apixaban was associated with a lower risk of recurrent ischemic stroke or systemic embolism compared with aspirin.<\/p>\n<hr>\n<p>This secondary analysis of a randomized clinical trial evaluates the association between hypertension with high-risk features and treatment effect.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In an exploratory analysis of the ARCADIA randomized clinical trial, hypertension with high\u2011risk features was associated with modification of antithrombotic treatment effects after cryptogenic stroke. Among patients without high\u2011risk hypertension features, apixaban was associated with a lower risk of recurrent ischemic stroke or systemic embolism compared with aspirin. This secondary analysis of a randomized clinical [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-235698","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=235698"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235698\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=235698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=235698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=235698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}